APAC Expands Specialized Manufacturing Capabilities Across High-Value Modalities

Key Takeaways

• APAC pharmaceutical manufacturing is expanding beyond conventional APIs and large-scale production into higher-value, technically complex modalities.

• India and China are adding specialized HPAPI and synthetic manufacturing capacity that requires advanced containment, purification, and analytical controls.

• South Korea and Singapore are developing capabilities spanning ADC bioconjugation, oligonucleotides, mRNA, biologics, and sterile drug products.

• New viral-vector and cell-therapy investments in Australia and Japan are broadening the region’s advanced-therapy manufacturing infrastructure.

• Sponsors evaluating APAC CDMOs must distinguish operational capacity from planned facilities and assess capabilities at the individual site, modality, and production-scale level.

Pharmaceutical manufacturing in the Asia-Pacific (APAC) region has long been associated with production scale, extensive supply networks, and established active pharmaceutical ingredient (API) capacity. That perception remains valid, but it no longer captures the full range of manufacturing activity developing across the region. New and expanded facilities are targeting high-potency APIs (HPAPIs), antibody–drug conjugates (ADCs), biologics, oligonucleotides, messenger RNA (mRNA), viral vectors, cell therapies, and advanced sterile drug products.

The scale of the existing pharmaceutical base provides an important foundation for this transition. India exported pharmaceutical products to 191 countries in 2024–2025, with exports totaling $30.5 billion, compared with $1.9 billion in 2000–2001.¹ Singapore, meanwhile, has developed a biopharmaceutical manufacturing network encompassing more than 60 plants that produce small molecule APIs, biologics, cell therapies, and ADCs. The country’s biopharmaceutical manufacturing output exceeded S$18 billion in 2023, and its facilities manufactured S$12.1 billion in products in 2024.²

However, the next phase of APAC manufacturing development is not occurring uniformly. Different national markets and individual companies are concentrating on distinct combinations of drug substance production, containment, bioconjugation, nucleic acid synthesis, advanced therapy manufacturing, and sterile drug product services. Some capabilities are already operating, while others remain under construction or are scheduled to become available later in the decade. The result is a regional manufacturing map defined less by interchangeability than by increasingly specialized clusters.

Expanding conventional production capacity generally involves adding equipment, production lines, or facility space within an established process model. Moving into complex modalities presents a different challenge. The necessary manufacturing environment may require dedicated containment, specialized upstream or downstream operations, modality-specific purification, distinct analytical methods, segregated production areas, or tightly controlled aseptic processing.

HPAPI manufacturing illustrates why facility design and operating controls must align with the properties of the product. Regulatory expectations for highly active or sensitizing compounds differ among jurisdictions, including requirements concerning when dedicated or segregated manufacturing areas are necessary.³ A manufacturing site that is suitable for a conventional API cannot therefore be assumed to possess the infrastructure, procedures, or containment strategy required for a potent compound.

The same principle applies across the other modalities now attracting investment in APAC. Oligonucleotides require specialized synthesis and purification platforms. Viral vectors involve interconnected cell culture, purification, filtration, and characterization processes. Sterile injectables require manufacturing environments designed around aseptic control. ADC production combines biologics capabilities with the handling of highly potent materials and bioconjugation operations.

These distinctions matter for pharmaceutical and biotechnology companies evaluating contract development and manufacturing organizations (CDMOs). A broad regional footprint or an extensive facility network may indicate manufacturing scale, but neither establishes that the required technical capabilities are available at the relevant site. Sponsors must assess the specific equipment, containment level, process expertise, analytical support, operating scale, and development services associated with each facility.

The expansion of HPAPI capacity provides one of the clearest examples of APAC manufacturers moving toward more technically demanding production. These facilities must control worker exposure and prevent potent materials from affecting other products or surrounding manufacturing activities. The required approach depends on the characteristics of the compound and the regulatory expectations governing the facility.

Several recent investments demonstrate the degree of specialization involved. Sai Life Sciences opened a 16,000-ft2 HPAPI manufacturing facility at its API campus in Bidar, India, in 2023. The facility was reported as capable of handling HPAPIs that require containment below 1 µg/m³.⁴ WuXi STA opened an HPAPI plant in Changzhou, China, in 2022 with reactors ranging from 250 to 3,000 liters and capabilities for compounds with occupational exposure limits as low as 10 ng/m³. The same site also supports linkers, oligonucleotides, and peptides.⁴

The combination of potent-compound handling with other specialized synthetic capabilities points toward a broader multimodality strategy. Rather than dedicating expansion exclusively to traditional API production, manufacturers are creating environments that can support several categories of technically challenging molecules. This model may allow facilities to apply related containment, purification, and analytical expertise across different programs, although the exact requirements still depend on the product and process.

ADC manufacturing extends the need for containment into a production model that also requires bioconjugation. Samsung Biologics operates a dedicated ADC facility at its Songdo campus that was designed specifically for HPAPI handling and functions separately from the company’s other biomanufacturing services. The facility supports bioconjugation using reactor systems with capacity up to a 500-liter train.⁵

The separation of the ADC operation from other biologics services illustrates how manufacturers are adapting facility configurations to the risks and technical demands of the modality. ADC programs bring together capabilities that have often resided in different parts of the pharmaceutical manufacturing sector. The biologic component, potent material, conjugation step, purification strategy, and analytical program must operate as parts of a connected process.

This convergence creates opportunities for CDMOs that can combine previously separate capabilities within a coordinated operating model. It also raises the standard for claiming end-to-end support. A provider may possess biologics capacity, HPAPI containment, or conjugation expertise without offering all three at the same location or scale. Sponsors must determine how the individual elements connect and where transfers between sites, organizations, or jurisdictions may be required.

Biologics manufacturing remains another major component of APAC’s specialized capacity buildout. Singapore offers a prominent example because its established biopharmaceutical base already spans small molecule APIs, biologics, cell therapies, and ADCs.² Recent investment plans indicate that the country’s role may continue to broaden through facilities designed to integrate research, development, scale-up, and manufacturing.

WuXi Biologics broke ground in 2024 on a 13.5-hectare contract research, development, and manufacturing organization (CRDMO) center in Singapore. The company announced a $1.4 billion investment and plans for 120,000 liters of biologics manufacturing capacity, along with approximately 1,500 employees once the center becomes fully operational.⁶

The capacity associated with the project remains planned rather than operational. That distinction is essential when assessing the current availability of APAC manufacturing services. Announced investments indicate where companies expect demand and technical requirements to develop, but sponsors cannot treat future capacity as equivalent to validated, functioning production infrastructure.

The Singapore project also reflects a broader movement toward integrated development and manufacturing campuses. Locating research, process development, scale-up, and production capabilities within a coordinated hub can reduce some of the organizational divisions that arise when programs move among separate service providers. The value of that model will depend on execution, operational readiness, and the extent to which technical knowledge transfers effectively between development and manufacturing groups.

Singapore’s existing concentration of biopharmaceutical plants gives such investments a different context than a standalone facility built in a market without a comparable manufacturing base. The country already hosts dozens of facilities working across multiple product categories, creating a setting in which biologics manufacturing can develop alongside sterile drug product, cell therapy, ADC, and synthetic modality capabilities.²

Oligonucleotide manufacturing is another area in which conventional small molecule infrastructure may not be sufficient. Current manufacturing technologies can consume large volumes of hazardous reagents and solvents and involve energy-intensive synthesis, purification, and isolation processes. These characteristics create waste, cost, and process development challenges that manufacturers must address through specialized technical platforms.⁷

The manufacturing burden extends beyond the synthesis reaction. Purification, isolation, material handling, waste management, quality control, and scale-up must function as an integrated process. As therapeutic programs move toward larger clinical studies or commercial supply, inefficient use of solvents, reagents, energy, or production time can become increasingly consequential.

South Korea’s ST Pharm publicly offers CDMO services across small molecules, oligonucleotides, and mRNA and describes its platform as extending from oligonucleotide production into broader RNA manufacturing. Its Sihwa and Banwol campuses include current good manufacturing practice (GMP) manufacturing, quality, and research and development functions.⁸

The combination of small molecule, oligonucleotide, and mRNA services demonstrates how manufacturers are assembling portfolios around related but distinct technical platforms. Oligonucleotides and mRNA should not be treated as interchangeable manufacturing categories. Their processes, materials, purification requirements, and product characteristics differ. Their presence within the same organization nevertheless reflects a strategic emphasis on nucleic acid–based modalities and the technical systems needed to support them.

Singapore is also attracting planned investment across specialized synthetic modalities. A 50-acre WuXi AppTec project is intended to provide API research, development, and manufacturing services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates.²

This type of multimodality site differs from a traditional API expansion focused primarily on increasing reactor volume. The planned service range requires the organization to accommodate multiple synthesis, purification, analytical, and containment models. Its future value will depend on whether these capabilities operate as genuinely differentiated platforms rather than as a collection of modality labels.

For biopharma companies evaluating manufacturing partners, the relevant questions include the scale available for each modality, the maturity of the process-development organization, the ability to manage solvent and waste burdens, and the relationship between synthesis and downstream purification. A company that lists oligonucleotide or mRNA capabilities may support early development, clinical manufacturing, commercial supply, or some combination of those stages. Those distinctions must be established during partner evaluation.

Viral vector manufacturing introduces a different combination of biological production and downstream processing requirements. Lentiviral vector bioprocessing can encompass producer-cell culture, transfection, bioreactor selection, purification, chromatography, tangential-flow filtration, and vector characterization.⁹ Performance at one stage can affect the demands placed on subsequent operations, making process integration particularly important.

Australia added a significant regional capability when the Viral Vector Manufacturing Facility opened in Sydney in October 2025. The facility describes itself as the country’s first clinical- and commercial-scale viral-vector CDMO and offers GMP production of lentiviral and adeno-associated viral (AAV) vectors. Its services include preclinical and clinical manufacturing at scales of up to 500 liters.¹⁰

The facility was backed by an AUS$134.5 million investment from the New South Wales government. That support reflects an effort to establish domestic infrastructure for a manufacturing category that requires specialized facilities, trained personnel, and connected development and production operations.

The Australian investment also adds geographic diversity to APAC’s advanced therapy manufacturing landscape. While several of the region’s largest pharmaceutical manufacturing hubs are concentrated in East and South Asia, the Sydney facility provides viral-vector capacity in Australia at both clinical and commercial scale. Its long-term significance will depend on utilization, operational performance, and the development of programs requiring regional vector supply.

Japan is expanding a related set of cell-therapy and advanced-biologics capabilities. AGC Biologics began offering cell-therapy process-development and clinical-manufacturing services at its Yokohama Technical Center in July 2025. A larger facility scheduled for 2027 is planned to support mammalian protein biologics, cell therapies, and mRNA from preclinical development through commercial manufacturing.¹¹

The operating technical center and the planned larger facility represent different stages of capacity development. The current site provides development and clinical-manufacturing services, while the future facility is intended to cover a wider range of modalities and development stages. Keeping those categories separate prevents announced commercial capability from being confused with services already available.

These investments suggest that APAC’s advanced therapy manufacturing base is developing through a series of targeted national and company-level projects. The region does not yet function as a uniform network in which equivalent viral vector or cell therapy services are available across markets. Instead, sponsors must identify which location offers the appropriate vector type, process scale, development support, analytical capability, and commercial pathway for a specific program.

Specialized drug substance capacity does not alone create an end-to-end manufacturing solution. Biologics, vaccines, and other injectable therapies must also be converted into sterile drug products using facilities and controls suited to aseptic processing. The U.S. Food and Drug Administration (FDA) maintains dedicated GMP guidance for sterile drug and biological products manufactured through aseptic processing, reflecting the distinct requirements associated with this production environment.¹²

Sterile manufacturing requires more than the presence of a filling line. The entire operating system must support contamination control, controlled material and personnel flows, appropriate equipment, and consistent execution. Different products may also require liquid filling, lyophilization, vial presentation, prefilled syringes, or specialized handling conditions.

Thermo Fisher Scientific opened a sterile drug manufacturing facility in Singapore in May 2023. The site includes rapid vaccine fill–finish capabilities and an automated aseptic filling line that supports small and large molecules.¹³ Its presence adds operating drug product capacity to a national manufacturing base that already encompasses biologics and other specialized modalities.

WuXi Biologics is also developing a modular biologics drug product facility as part of its Singapore hub. Fabrication began in 2025, and the announced design includes three prefilled-syringe lines and two vial lines for liquid and lyophilized products. Operations are expected to begin in 2027.¹⁴

The Thermo Fisher facility and the planned WuXi Biologics expansion illustrate the need to distinguish current from future supply options. One represents operating sterile capacity, while the other describes a facility still moving toward its expected launch. Both contribute to the broader development of Singapore as a location where drug substance and drug product capabilities can coexist, but only existing, qualified lines can support immediate manufacturing demand.

For biopharma companies, the relationship between drug substance and drug product sites can shape technology transfer, scheduling, logistics, and accountability. A CDMO that offers both services within the same regional network may reduce the number of external interfaces, but integration must be evaluated rather than assumed. The relevant questions include whether the services operate at the same site, whether they share quality and project management systems, and whether the drug product format required by the program is available at the necessary scale.

The verified investments do not point toward a single APAC manufacturing model. They show a network of markets and companies developing different areas of technical strength.

India and China provide examples of new HPAPI capacity and specialized synthetic manufacturing. South Korea combines ADC bioconjugation with oligonucleotide and mRNA capabilities. Singapore has attracted biologics, sterile drug product, multimodality synthetic, cell therapy, and ADC manufacturing activity. Australia has established clinical- and commercial-scale viral vector capacity, while Japan is expanding cell therapy development and manufacturing alongside planned biologics and mRNA services.

This distribution can create opportunities for sponsors seeking alternatives to a single-country or single-provider manufacturing strategy. It can also introduce complexity when a program requires several capabilities that are not located within the same organization or national market. An ADC program, for example, may require biologic drug substance, potent payload handling, conjugation, purification, analytical testing, and sterile filling. A cell or gene therapy may need vector manufacturing, cell processing, specialized testing, and clinical or commercial distribution.

The value of an APAC manufacturing strategy therefore depends on the fit between the modality and the particular facility. Regional presence alone does not establish technical suitability. Sponsors must determine which capabilities are operational, which remain planned, what production scales are available, and whether the services required across development and manufacturing are connected.

A cluster-based view also provides a more accurate framework than treating APAC as a uniform low-cost manufacturing destination. The investments described here emphasize specialized facilities, dedicated operating environments, advanced processing platforms, and integrated development services. Their competitive position will depend on technical execution, quality performance, and the ability to move programs reliably from development into larger-scale supply.

As CDMOs add high-value modalities, the basis of competition becomes more technically specific. Facility footprint and total reactor volume remain relevant, but they do not fully describe the ability to support a complex product. Sponsors increasingly need evidence of dedicated containment, modality-specific process development, integrated analytical support, appropriate purification, and a credible path from clinical to commercial manufacturing.

The distinction between breadth and depth becomes especially important. A provider may list biologics, oligonucleotides, ADCs, viral vectors, or sterile injectables among its services, but the actual offering may vary by site, scale, development phase, or production format. A modality listed at the corporate level may be available only through a recently opened facility, a future project, or a separate location that requires an additional technology transfer.

Operating status must therefore remain central to partner assessment. Several major APAC projects described here are scheduled to open or expand in 2027. These investments may add substantial capability, but they should not be counted as current capacity until the facilities are complete and operational. Sponsors planning future supply may consider the expected timelines, while programs with near-term needs must rely on existing infrastructure.

Integration is another potential differentiator. Samsung Biologics’ dedicated bioconjugation operation, the planned WuXi Biologics research-to-manufacturing hub, ST Pharm’s nucleic acid–focused service portfolio, and AGC Biologics’ expansion from clinical cell-therapy services toward a broader multimodality facility each reflect different approaches to connecting specialized capabilities.

The strength of these models will depend on how well their individual functions operate together. True integration requires more than placing services under the same corporate name. Development knowledge must transfer into manufacturing, analytical methods must remain suitable as processes scale, quality systems must support movement between stages, and project governance must coordinate activities across technical groups and sites.

For APAC CDMOs, specialization offers a route into programs in which manufacturing strategy is closely tied to product viability. It also raises customer expectations. Companies investing in complex modalities must demonstrate that new buildings, equipment, and service announcements translate into reproducible operations, appropriately trained teams, and reliable supply.

1. “India’s Pharmaceuticals in Global Healthcare: From Domestic Production to International Markets.” Press Information Bureau, Government of India. 21 Mar. 2026.

2. “Biotechnology & Pharmaceuticals in Singapore.” Singapore Economic Development Board. 11 Mar. 2026.

3. Petrelli, Fabio, et al. “The Requirements for Manufacturing Highly Active or Sensitising Drugs Comparing Good Manufacturing Practices.” Acta Biomedica Atenei Parmensis. 90: 288–299 (2019).

4. “The CDMO/CMO Report: High-Potency API Manufacturing.” DCAT Value Chain Insights. 13 Jul. 2023.

5. “End-to-End Bioconjugation Development & Manufacturing.” Samsung Biologics. Accessed 22 Jul. 2026.

6. “WuXi Biologics Breaks Ground on CRDMO Center in Singapore.” WuXi Biologics. 19 Mar. 2024.

7. Andrews, Benjamin I, et al. “Sustainability Challenges and Opportunities in Oligonucleotide Manufacturing.” The Journal of Organic Chemistry. 86: 49–61 (2021).

8. “ST PHARM.” ST Pharm. Accessed 22 Jul. 2026.

9. Perry, Christopher, and Andrea CME Rayat. “Lentiviral Vector Bioprocessing.” Viruses. 13: 268 (2021).

10. “Australia’s First Clinical and Commercial-Scale Viral Vector CDMO, VVMF, Opens in Sydney.” Viral Vector Manufacturing Facility. 28 Oct. 2025.

11. “AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need.” AGC Biologics. 25 Jun. 2025.

12. Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice: Guidance for Industry. U.S. Food and Drug Administration. Oct. 2004.

13. “Thermo Fisher Scientific Expands Steriles Manufacturing and Research Capabilities in Asia-Pacific Region.” Thermo Fisher Scientific. 19 May 2023.

14. “WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication.” WuXi Biologics. 29 Jul. 2025.